课题基金 / 基金详情

PF-04494700 IN PARTICIPANTS WITH MILD-TO-MODERATE ALZHEIMERS'S DISEASE

PF-04494700 IN PARTICIPANTS WITH MILD-TO-MODERATE ALZHEIMERS'S DISEASE
PF-04494700 适用于患有轻度至中度阿尔茨海默病的参与者
批准号:
7719083
负责人:
Paul S. Aisen
金额:
$0.29万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2009-03-31

项目摘要

项目成果

Paul S. Aisen的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to collect, store, and use samples to investigate possible associations between genomic and metabonomic variation in relation to response to the study drugs and in relation to characteristics of the disease/condition under study in the associated clinical trial, and related conditions. In addition, samples may be used as controls in genomic and metabonomic investigations of the causes, natural history, and other aspects of important diseases and conditions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
  • 批准号:
    10554282
  • 项目类别:
  • 资助金额:
    $694.16万
  • 财政年份:
    2019
  • 负责人:
    Paul S. Aisen
  • 依托单位:
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
  • 批准号:
    10358480
  • 项目类别:
  • 资助金额:
    $694.33万
  • 财政年份:
    2019
  • 负责人:
    Paul S. Aisen
  • 依托单位:
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
  • 批准号:
    9930020
  • 项目类别:
  • 资助金额:
    $694.49万
  • 财政年份:
    2019
  • 负责人:
    Paul S. Aisen
  • 依托单位:
Combination anti-amyloid therapy for preclinical Alzheimer's disease